Literature DB >> 22393150

Characterization of Ly108 in the thymus: evidence for distinct properties of a novel form of Ly108.

Mala Dutta1, Pamela L Schwartzberg.   

Abstract

Ly108 (CD352) is a member of the signaling lymphocyte activation molecule (SLAM) family of receptors that signals through SLAM-associated protein (SAP), an SH2 domain protein that can function by the recruitment of Src family kinases or by competition with phosphatases. Ly108 is expressed on a variety of hematopoietic cells, with especially high levels on developing thymocytes. We find that Ly108 is constitutively tyrosine phosphorylated in murine thymi in a SAP- and Fyn kinase-dependent manner. Phosphorylation of Ly108 is rapidly lost after thymocyte disaggregation, suggesting dynamic contact-mediated regulation of Ly108. Similar to recent reports, we find at least three isoforms of Ly108 mRNA and protein in the thymus, which are differentially expressed in the thymi of C57BL/6 and 129S6 mice that express the lupus-resistant and lupus-prone haplotypes of Ly108, respectively. Notably, the recently described novel isoform Ly108-H1 is not expressed in mice having the lupus-prone haplotype of Ly108, but is expressed in C57BL/6 mice. We further provide evidence for differential phosphorylation of these isoforms; the novel Ly108-H1does not undergo tyrosine phosphorylation, suggesting that it functions as a decoy isoform that contributes to the reduced overall phosphorylation of Ly108 seen in C57BL/6 mice. Our study suggests that Ly108 is dynamically regulated in the thymus, shedding light on Ly108 isoform expression and phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22393150      PMCID: PMC3311760          DOI: 10.4049/jimmunol.1103226

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

1.  Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus.

Authors:  B P Tsao; R M Cantor; K C Kalunian; C J Chen; H Badsha; R Singh; D J Wallace; R C Kitridou; S L Chen; N Shen; Y W Song; D A Isenberg; C L Yu; B H Hahn; J I Rotter
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

2.  Polygenic control of susceptibility to murine systemic lupus erythematosus.

Authors:  L Morel; U H Rudofsky; J A Longmate; J Schiffenbauer; E K Wakeland
Journal:  Immunity       Date:  1994-06       Impact factor: 31.745

3.  Intrathymic signalling in immature CD4+CD8+ thymocytes results in tyrosine phosphorylation of the T-cell receptor zeta chain.

Authors:  T Nakayama; A Singer; E D Hsi; L E Samelson
Journal:  Nature       Date:  1989-10-19       Impact factor: 49.962

4.  SAP regulates T(H)2 differentiation and PKC-theta-mediated activation of NF-kappaB1.

Authors:  Jennifer L Cannons; Li J Yu; Brenna Hill; Lilia A Mijares; Derek Dombroski; Kim E Nichols; Anthony Antonellis; Gary A Koretzky; Kevin Gardner; Pamela L Schwartzberg
Journal:  Immunity       Date:  2004-11       Impact factor: 31.745

5.  Constitutive tyrosine phosphorylation of the T-cell receptor (TCR) zeta subunit: regulation of TCR-associated protein tyrosine kinase activity by TCR zeta.

Authors:  N S van Oers; W Tao; J D Watts; P Johnson; R Aebersold; H S Teh
Journal:  Mol Cell Biol       Date:  1993-09       Impact factor: 4.272

6.  Immune deficiency in the X-linked lymphoproliferative syndrome. I. Epstein-Barr virus-specific defects.

Authors:  S Harada; K Sakamoto; J K Seeley; T Lindsten; T Bechtold; J Yetz; G Rogers; G Pearson; D T Purtilo
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

7.  Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome.

Authors:  K E Nichols; D P Harkin; S Levitz; M Krainer; K A Kolquist; C Genovese; A Bernard; M Ferguson; L Zuo; E Snyder; A J Buckler; C Wise; J Ashley; M Lovett; M B Valentine; A T Look; W Gerald; D E Housman; D A Haber
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

8.  Soluble and membrane-bound forms of signaling lymphocytic activation molecule (SLAM) induce proliferation and Ig synthesis by activated human B lymphocytes.

Authors:  J Punnonen; B G Cocks; J M Carballido; B Bennett; D Peterson; G Aversa; J E de Vries
Journal:  J Exp Med       Date:  1997-03-17       Impact factor: 14.307

9.  The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM.

Authors:  J Sayos; C Wu; M Morra; N Wang; X Zhang; D Allen; S van Schaik; L Notarangelo; R Geha; M G Roncarolo; H Oettgen; J E De Vries; G Aversa; C Terhorst
Journal:  Nature       Date:  1998-10-01       Impact factor: 49.962

10.  Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene.

Authors:  A J Coffey; R A Brooksbank; O Brandau; T Oohashi; G R Howell; J M Bye; A P Cahn; J Durham; P Heath; P Wray; R Pavitt; J Wilkinson; M Leversha; E Huckle; C J Shaw-Smith; A Dunham; S Rhodes; V Schuster; G Porta; L Yin; P Serafini; B Sylla; M Zollo; B Franco; A Bolino; M Seri; A Lanyi; J R Davis; D Webster; A Harris; G Lenoir; G de St Basile; A Jones; B H Behloradsky; H Achatz; J Murken; R Fassler; J Sumegi; G Romeo; M Vaudin; M T Ross; A Meindl; D R Bentley
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

View more
  9 in total

1.  Expansion of an osteopontin-expressing T follicular helper cell subset correlates with autoimmunity in B6.Sle1b mice and is suppressed by the H1-isoform of the Slamf6 receptor.

Authors:  Marton Keszei; Cynthia Detre; Wilson Castro; Erica Magelky; Michael O'Keeffe; Katalin Kis-Toth; George C Tsokos; Ninghai Wang; Cox Terhorst
Journal:  FASEB J       Date:  2013-04-29       Impact factor: 5.191

2.  The receptor Ly108 functions as a SAP adaptor-dependent on-off switch for T cell help to B cells and NKT cell development.

Authors:  Robin Kageyama; Jennifer L Cannons; Fang Zhao; Isharat Yusuf; Christopher Lao; Michela Locci; Pamela L Schwartzberg; Shane Crotty
Journal:  Immunity       Date:  2012-06-07       Impact factor: 31.745

3.  A role for Ly108 in the induction of promyelocytic zinc finger transcription factor in developing thymocytes.

Authors:  Mala Dutta; Zachary J Kraus; Julio Gomez-Rodriguez; Sun-Hee Hwang; Jennifer L Cannons; Jun Cheng; Sang-Yun Lee; David L Wiest; Edward K Wakeland; Pamela L Schwartzberg
Journal:  J Immunol       Date:  2013-01-25       Impact factor: 5.422

4.  T/B-cell interactions are more transient in response to weak stimuli in SLE-prone mice.

Authors:  Parisa Sinai; Igor M Dozmorov; Ran Song; Pamela L Schwartzberg; Edward K Wakeland; Christoph Wülfing
Journal:  Eur J Immunol       Date:  2014-11-12       Impact factor: 5.532

5.  Multiple tolerance defects contribute to the breach of B cell tolerance in New Zealand Black chromosome 1 congenic mice.

Authors:  Nan-Hua Chang; Kieran P Manion; Christina Loh; Evelyn Pau; Yuriy Baglaenko; Joan E Wither
Journal:  PLoS One       Date:  2017-06-19       Impact factor: 3.240

6.  SLAMF6 clustering is required to augment T cell activation.

Authors:  Matthew A Dragovich; Kieran Adam; Marianne Strazza; Anna S Tocheva; Michael Peled; Adam Mor
Journal:  PLoS One       Date:  2019-06-14       Impact factor: 3.240

Review 7.  SLAM Associated Protein Signaling in T Cells: Tilting the Balance Toward Autoimmunity.

Authors:  Yevgeniya Gartshteyn; Anca D Askanase; Adam Mor
Journal:  Front Immunol       Date:  2021-04-16       Impact factor: 7.561

8.  T-B Lymphocyte Interactions Promote Type 1 Diabetes Independently of SLAM-Associated Protein.

Authors:  Rachel H Bonami; Lindsay E Nyhoff; Dudley H McNitt; Chrys Hulbert; Jamie L Felton; Peggy L Kendall; James W Thomas
Journal:  J Immunol       Date:  2020-11-16       Impact factor: 5.422

9.  CRISPR-Mediated Triple Knockout of SLAMF1, SLAMF5 and SLAMF6 Supports Positive Signaling Roles in NKT Cell Development.

Authors:  Bonnie Huang; Julio Gomez-Rodriguez; Silvia Preite; Lisa J Garrett; Ursula L Harper; Pamela L Schwartzberg
Journal:  PLoS One       Date:  2016-06-03       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.